These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Lau LM; Nugent JK; Zhao X; Irwin MS Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533 [TBL] [Abstract][Full Text] [Related]
4. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546 [TBL] [Abstract][Full Text] [Related]
6. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464 [TBL] [Abstract][Full Text] [Related]
7. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100 [TBL] [Abstract][Full Text] [Related]
8. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343 [TBL] [Abstract][Full Text] [Related]
9. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Vaseva AV; Marchenko ND; Moll UM Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846 [TBL] [Abstract][Full Text] [Related]
10. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692 [TBL] [Abstract][Full Text] [Related]
11. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. Davaadelger B; Shen H; Maki CG PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055 [TBL] [Abstract][Full Text] [Related]
12. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161 [TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Saha MN; Jiang H; Chang H Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817 [TBL] [Abstract][Full Text] [Related]
14. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Ray RM; Bhattacharya S; Johnson LR Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030 [TBL] [Abstract][Full Text] [Related]
15. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Gamble LD; Kees UR; Tweddle DA; Lunec J Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332 [TBL] [Abstract][Full Text] [Related]
17. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Michaelis M; Rothweiler F; Barth S; Cinatl J; van Rikxoort M; Löschmann N; Voges Y; Breitling R; von Deimling A; Rödel F; Weber K; Fehse B; Mack E; Stiewe T; Doerr HW; Speidel D; Cinatl J Cell Death Dis; 2011 Dec; 2(12):e243. PubMed ID: 22170099 [TBL] [Abstract][Full Text] [Related]
18. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807 [TBL] [Abstract][Full Text] [Related]
20. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53. He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]